Radiation protection by deferiprone in animal models

Hemoglobin

Volumn 30, Issue 2, 2006, Pages 201-208

  Fukuda, Satoshi ^a   Ikeda, Mizuyo ^a   Anzai, Kazunori ^a   Suzuki, Masao ^a   Katoh, Akira ^b   Kontoghiorghes, George ^c  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b SEIKEI UNIVERSITY   (Japan)

^c Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

Author keywords

Chelation; Deferiprone (L1); Depleted uranium (DU); Rat; X ray exposure

Indexed keywords

DEFERIPRONE; URANIUM;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; CHELATION; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; MALE; NONHUMAN; RADIATION EXPOSURE; RADIATION INJURY; RADIATION PROTECTION; RAT; X RAY;

ADMINISTRATION, ORAL; ANIMALS; CHELATING AGENTS; CHELATION THERAPY; DRUG EVALUATION, PRECLINICAL; FECES; FEMUR; KIDNEY; KIDNEY FUNCTION TESTS; LIVER; MALE; MICE; MICE, INBRED C3H; MUSCLE, SKELETAL; PYRIDONES; RADIATION INJURIES, EXPERIMENTAL; RADIATION-PROTECTIVE AGENTS; RATS; RATS, WISTAR; TISSUE DISTRIBUTION; URANIUM; URANYL NITRATE; X-RAYS;

ANIMALIA;

EID: 33745562795     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.1080/03630260600642484     Document Type: Conference Paper

References (15)

1. Chen J, Meyerhof DP, Tracy BL. Model results of kidney burdens from uranium intakes. Health Phys 2004; 86(1):3-11.
2. Craft E, Abu-Qare A, Flaherty M, Garofolo M, Rincavage H, Abou-Donia M. Depleted and natural uranium: chemistry and toxicological effects. J Toxicol Environ Health B Crit Rev 2004; 7(4):297-317.
3. Durakovic A. Medical effects of internal contamination with uranium. Croat Med J 1999; 40(1):49-66.
4. Fukuda S, Iida H, Ikeda M, Yan X, Xie Y. Toxicity of uranium and the removal effects of CBMIDA and EHBP in simulated wounds of rats. Health Phys 2005; 89(1):81-89.
5. Leggett RW. The behavior and chemical toxicity of U in the kidney: a reassessment. Health Phys 1989; 57(3):365-383.
6. Mould RF. Depleted uranium and radiation-induced lung cancer and leukaemia. Br J Radiol 2001; 74(884):677-683.
7. Sztajnkrycer MD, Otten EJ. Chemical and radiological toxicity of depleted uranium. Milit Med 2004; 169(3):212-216.
8. Stradling N, Hodgson A, Berard P, Etherington G, Fell T, LeGuen B. Anomalies between radiological and chemical limits for uranium after inhalation by workers and the public. Radiat Prot Dosim 2003; 105(1-4):175-178.
9. Toohey RE. Excretion of depleted uranium by Gulf War veterans. Radiat Prot Dosim 2003; 105(1-4): 171-174.
10. Gwiazda RH, Squibb K, McDiarmid K, Smith D. Detection of depleted uranium in urine of veterans from the 1991 Gulf War. Health Phys 2004; 86(1):12-18.
11. Hooper FJ, Squibb KS, Siegel EL, McPhaul K, Keogh JP. Elevated urine uranium excretion by soldiers with retained uranium shrapnel. Health Phys 1999; 77(5):512-519.
12. Kontoghiorghes GJ, Sitarou M, Pattichi K, Kolnagou A. Iron overload toxicity and new therapeutic strategies with the orally effective chelating drug deferiprone (L1). Biomarkers and Environment 2001; 4(Suppl 1):16-21.
13. Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem 2004; 11(16):2161-2183.
14. Volf V, Kontoghiorghes GJ. Retention of injected plutonium and americium in mice and rat after oral treatment with DTPA, Desferrioxamine and Alpha-ketohydroxypyridines. Drugs Today 1992; 28(Suppl A):169-172.
15. Berrington de Gonzalez A, Darby S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet 2004; 363(9406):345-351.